Author

Lauryn E. Flannagan

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract A036: Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with an unmet need for novel precision based therapies. While KRAS canonically drives tumor progression, MYC amplification has emerged as a critical downstream resistance mechanism. Efforts have been made to elucidate the role of MYC amplification in PDAC...

Audrey G. Sawyer, Lauryn E. Flannagan, Paulina N. Esguerra et al. · Cancer Research · 0 citations

Sep 2026

Abstract B043: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer related mortality with a critical need for novel therapeutic strategies. Cyclin dependent kinase 9 (CDK9) is a transcriptional regulator of RNA polymerase II (Pol II) by phosphorylation of serine residues on the C terminal domain of the pos...

Michela Cadarso, Paulina N. Esguerra, Lauryn E. Flannagan et al. · Cancer Research · 0 citations

#protein folding Sep 2026

Abstract B052: Understanding latent resistance mechanisms and their phenotypes in pancreatic cancer organoids under KRASG12D inhibition

The rate of acquired resistance to Zoldonrasib was found to be rapid in PCO models and independent of EGF stimulation, and opposing signaling pathway activation in resistant PCOs to Zoldonrasib at 200nM dependent upon EGF stimulation was suggested.

Lauryn E. Flannagan, Michela Cadarso, Audrey G. Sawyer et al. · Cancer Research · 0 citations